Endorsed Legislation

Members of the Blue Dog Coalition actively work to build bipartisan support for legislation that supports their commitment to the financial stability and national security of the country.  Whether it is a Republican idea or a Democratic idea, members of the Blue Dog Coalition introduce and work to pass legislation they believe to restore fiscal accountability, strengthen our economy and help the American people.

Legislation endorsed by the Blue Dog Coalition in the 116th Session of Congress:

H.R.270, Government Shutdown Impact Report Act of 2019 (Rep. Tom O’Halleran, AZ-01)
In the event of a government shutdown, the Shutdown Impact Report Act of 2019 requires the Congressional Budget Office (CBO) to prepare a daily report on the economic cost and the damage to our national security.

 

H.R. 129, No Budget, No Pay Act (Rep. Jim Cooper, TN-05)
The No Budget, No Pay Act halts paychecks for all House and Senate members if they miss annual deadlines for budget and appropriations bills. It prohibits members from receiving pay for each day past Sept. 30 that budget and spending bills don’t pass. Under this legislation, members are not allowed to recover the pay retroactively.

 

H.R. 1781, Payment Commission Act (Rep. Tom O’Halleran, AZ-01)
The Payment Commission Act provides Congress’ independent advisory commissions, the Medicare Payment Advisory Commission (MedPAC) and the Medicaid and CHIP Payment and Access Commission (MACPAC), access to certain drug pricing data to help those commissions make recommendations to Congress on how to improve the Medicare and Medicaid programs and lower prescription drug prices. This legislation will increase transparency and help provide recommendations to Congress that are necessary to create policy reforms that help patients.

 

H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act (Rep. Kurt Schrader, OR-05)
The BLOCKING Act keeps drug prices down by increasing competition in the generic drug market. Current law awards 180 days of exclusivity on the market to a drug manufacturer when they are the first to file a generic drug application with the FDA for a drug for which there is no generic. The 180 days begins once the manufacturer starts marketing the drug, but even before the manufacturer begins marketing, all other generic competitors are blocked from coming to market. This allows some manufacturers to “park” the exclusivity before receiving final approval, blocking competition for more than the 180 days intended by the law. In these cases, no other generics can come to the market until the first manufacturer receives final approval, begins marketing the drug, and the subsequent 180 days have passed. The BLOCKING Act would stop first generic drug “parking.” Under the BLOCKING Act, if a second generic drug application is blocked from receiving approval solely due to a first generic drug manufacturer parking their exclusivity at the tentative approval stage, the 180 days immediately begins to run, preventing limitless delays for other generics to come to the market.

 

H.Res.246, Opposing efforts to delegitimize the State of Israel and the Global Boycott, Divestment, and Sanctions Movement targeting Israel (Rep. Brad Schneider, IL-10)
This bipartisan resolution supports a two-state solution and opposes efforts to delegitimize the state of Israel and the Global Boycott, Divestment, and Sanctions (BDS) Movement targeting Israel.

 

H.J. Res. 55, Balanced Budget Amendment (Rep. Ben McAdams, UT-04)
H.J. Res. 55 would amend the U.S. Constitution to prohibit the federal government from spending more than it receives in any given fiscal year, except in the cases of war or recession. The Amendment also generally prohibits a court from enforcing this requirement by ordering cuts to Social Security or Medicare payments. The Amendment requires the President to annually submit to Congress a budget in which total outlays do not exceed total receipts. It also prohibits federal total outlays for a fiscal year from exceeding total receipts for that fiscal year.

Issues: